BFG
PACB icon

Bleakley Financial Group’s Pacific Biosciences PACB Stock Holding History

Bleakley Financial Group’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-14,389
Closed -$24.5K – 1095
2024
Q3 		$24.5K Sell
14,389
-6,582
-31% -$10.8K ﹤0.01% 1016
2024
Q2 		$28.7K Buy
+20,971
New +$42.3K ﹤0.01% 999

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bleakley Financial Group's PACB Position: Q4 2024 in Review

Bleakley Financial Group sold out of Pacific Biosciences (PACB) in Q4 2024, closing a stake of 14,389 shares — an estimated $24.5K sold.

Bleakley Financial Group first reported a position in PACB in Q2 2024 and held it in 2 quarters. The position peaked at $28.7K in Q2 2024. 226 funds tracked by Wall St. Rank hold PACB as of Q4 2024.

  • Bleakley Financial Group reported no remaining Pacific Biosciences position as of Q4 2024 after selling out during the quarter.
  • Bleakley Financial Group sold 14,389 Pacific Biosciences shares in Q4 2024, an estimated $24.5K.
  • Bleakley Financial Group first reported a position in Pacific Biosciences in Q2 2024 and held it in 2 quarters.
  • Bleakley Financial Group's Pacific Biosciences position peaked at $28.7K in Q2 2024.
  • 226 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2024.

Based on Bleakley Financial Group's 13F filing for Q4 2024, filed 27 Jan 2025.